NCT04139577View on ClinicalTrials.gov

FMT In High-Risk Acute GVHD After ALLO HCT

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 18, 2021

Primary Completion Date

August 3, 2022

Study Completion Date

January 5, 2023

Conditions
Acute Graft-Versus-Host Disease (Gvhd) GradeHematopoietic Cell TransplantationFecal Microbiota Transplant
Interventions
BIOLOGICAL

Fecal Microbiota Transplant

FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

American Cancer Society, Inc.

OTHER

lead

Massachusetts General Hospital

OTHER